Navigation Links
Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Date:5/10/2013

tion, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for further research and development, regulatory review or approval or continued marketing; Arena's ability to obtain and defend patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo PartnersCindy McGee, Vice President,

David Schull, PresidentInvestor Relations & Alliance Management

david.schull@russopartnersllc.comcmcgee@arenapharm.com

858.717.2310858.453.7200, ext. 1479
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BIOCOM Applauds Arena Pharmaceuticals Commitment to Innovation, Contributions to Southern California Life Science Community
2. Carena Launches 24/7 Virtual Care Delivery Service for Hospital Systems and Primary Care Clinics
3. Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
4. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, May 2
5. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
6. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
7. Arena Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
8. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, March 4
9. Proposed Regulatory Uniformity to Boost Venture Capital Investments in Healthcare Arena, Says Frost & Sullivan
10. Arena Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference
11. Arena Pharmaceuticals and Ildong Pharmaceutical Enter Into Co-Development and License Agreement for Temanogrel, a Novel Agent for Thrombotic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... SHENZHEN, China , July 7, 2015 /PRNewswire/ -- ... ), a leading developer, manufacturer and marketer of ... to acquire the remaining stake in Wuhan Dragonbio ... million. Dragonbio is a domestic ... joint and other surgical products. Prior to today,s ...
(Date:7/7/2015)... 2015 EnteroMedics Inc. (NASDAQ: ETRM ), ... technology to treat obesity, metabolic diseases, and other gastrointestinal ... offering of 32,000,000 units. Each unit consists of one share ... purchase one share of common stock at a purchase ... units in the offering would result in them beneficially ...
(Date:7/7/2015)... July 7, 2015 Oasmia ... of drugs within human and veterinary oncology, today ... in the United States , ... leading companion animal therapeutic.      (Logo: ... ) , Paccal Vet-CA1 was ...
Breaking Medicine Technology:Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 2Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 3Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3Oasmia Pharmaceutical Launches US Brand and Sales Platform 2
... , , , ... service Contract Research Organization (CRO) founded in India, today announced the ... Application Suite (OLSAS) by going live with Oracle Siebel Clinical Trial ... , "We are excited to have the rollout of ...
... Aug. 5 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: ... a New Drug Submission (NDS) with the Therapeutic Products ... the antidepressant trazodone. , "We are pleased to file ... R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. ...
Cached Medicine Technology:SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite 2Labopharm files New Drug Submission with Health Canada for novel antidepressant 2Labopharm files New Drug Submission with Health Canada for novel antidepressant 3
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... Healthpointe ... pain management team. Dr. Alupay, an anesthesiologist and pain management specialist, will be evaluating ... as well as neurological conditions. , After receiving his Bachelor of Science in Biology ...
(Date:7/7/2015)... ... July 07, 2015 , ... FSAstore.com today announced the ... HSA holders. HSAstore.com makes it simple to use, spend and manage HSA funds with ... their accounts. , According to a report by Devenir , approximately 13.8 ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... relations, marketing, and creative design firm, today announced that TimberNook ( http://www.timbernook.com/ ... and social media campaign, content strategy, and marketing launch package for new ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... (NIWH) have jointly announced a partnership focused on providing knowledge organizing and differential ... The study will be conducted with NIWH trained patient health educators, utilizing the ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... law announce the launch of their new website, the Invokana Ketoacidosis Lawsuit ... FDA warning*, and serves as a resource for persons wishing to learn more ...
Breaking Medicine News(10 mins):Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 3Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 2Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 3Health News:TimberNook Selects Calypso Communications for PR, Social Media and Content Strategy 2Health News:Isabel Healthcare and the National Institute of Whole Health Announce Partnership for a Pilot Study Using the Isabel Diagnostic Support Tool and Knowledge Organizer 2Health News:Isabel Healthcare and the National Institute of Whole Health Announce Partnership for a Pilot Study Using the Isabel Diagnostic Support Tool and Knowledge Organizer 3Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 2Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 3
... ... ... , ... , , , ...
... Benefit from Fosamax, Boniva, Zometa does not apply to obese ... types of bone-building drugs used to prevent and treat osteoporosis ... research. , The study, which included 6,000 Wisconsin women aged ... such as Fosamax, Boniva and Zometa for more than two ...
... ... announced the acquisition of Rainbow Medical Center, an independent medical group providing care for more ... the Fremont Medical Centers Division of HealthCare Partners of Nevada. , ... (PRWEB) March 5, 2010 -- HealthCare Partners of Nevada, ...
... ... Six Sigma and national best selling author reveals The Great Discovery®, a ... beyond. In this sense, it is a way that virtually any ... Great Discovery® is a highly structured and systematic way of thinking that ...
... 39th Annual Meeting of the American Association for ... Convention Center in Washington, DC, lead researcher M. ... poster of a study titled "Epithelial-to-Endothelial Transition: An ... and a team of researchers have reported that ...
... ... ... ... ...
Cached Medicine News:Health News:Health Diagnostic Laboratory Inc. (HDL, Inc.) Launches Community Initiative, It Starts with the Heart 2Health News:Health Diagnostic Laboratory Inc. (HDL, Inc.) Launches Community Initiative, It Starts with the Heart 3Health News:Certain Bone Drugs May Lower Breast Cancer Risk 2Health News:HealthCare Partners of Nevada and Rainbow Medical Center Join Forces 2Health News:Co-Creator of Six Sigma Unveils “The Great Discovery” ... the 4th Generation of Six Sigma 2Health News:SarahCare(R) and Posit Science Corporation(R) Join Forces to Bring Brain Fitness to Seniors at SarahCare(R) of Minnesota 2Health News:SarahCare(R) and Posit Science Corporation(R) Join Forces to Bring Brain Fitness to Seniors at SarahCare(R) of Minnesota 3Health News:SarahCare(R) and Posit Science Corporation(R) Join Forces to Bring Brain Fitness to Seniors at SarahCare(R) of Minnesota 4Health News:SarahCare(R) and Posit Science Corporation(R) Join Forces to Bring Brain Fitness to Seniors at SarahCare(R) of Minnesota 5
... single liquid stable reagent offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The proprietary ... reagent provides a long shelf life ...
... powder reagent once reconstituted offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The proprietary ... reagent provides a long shelf life ...
LCD chart display...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
Medicine Products: